Heart Center

Home > Specialties > Heart Center > Warfarin Therapy study

Warfarin Therapy study

Regions Hospital participates in Warfarin Therapy Study

Warfarin is often prescribed to patients who have atrial fibrillation or a risk for forming clots. Many patients who are having a pacemaker or defibrillator implanted are on warfarin therapy. The Regions Hospital Heart Center developed a study published in Heart Rhythm Journal to determine whether continuing warfarin therapy while undergoing a pacemaker or defibrillator implantation was beneficial to the patient.

Researchers found that patients who continued taking warfarin had a lower incidence of bleeding such as forming a pocket hematoma (a collection of blood outside of a blood vessel). Patients also had a shorter hospital stay than those who stopped warfarin therapy for their procedure.

The study concluded that continuing warfarin therapy appears to be a safe and cost-effective approach for patients undergoing a pacemaker or defibrillator implantation and in patients with moderate to high blood clot risk. The study was supported in part by “Discovery Grants” from the HealthPartners Research Foundation.